Cimino Daniela, Fuso Luca, Sfiligoi Christian, Biglia Nicoletta, Ponzone Riccardo, Maggiorotto Furio, Russo Giandomenico, Cicatiello Luigi, Weisz Alessandro, Taverna Daniela, Sismondi Piero, De Bortoli Michele
Institute for Cancer Research and Treatment, Unit of Gynecological Oncology, University of Turin Medical School, Candiolo, Turin, Italy.
Int J Cancer. 2008 Sep 15;123(6):1327-38. doi: 10.1002/ijc.23660.
Gene expression profiles were studied by microarray analysis in 2 sets of archival breast cancer tissues from patients with distinct clinical outcome. Seventy-seven differentially expressed genes were identified when comparing 30 cases with relapse and 30 cases without relapse within 72 months from surgery. These genes had a specific ontological distribution and some of them have been linked to breast cancer in previous studies: AIB1, the two keratin genes KRT5 and KRT15, RAF1, WIF1 and MSH6. Seven out of 77 differentially expressed genes were selected and analyzed by qRT-PCR in 127 cases of breast cancer. The expression levels of 6 upregulated genes (CKMT1B, DDX21, PRKDC, PTPN1, SLPI, YWHAE) showed a significant association to both disease-free and overall survival. Multivariate analysis using the significant factors (i.e., estrogen receptor and lymph node status) as covariates confirmed the association with survival. There was no correlation between the expression level of these genes and other clinical parameters. In contrast, SERPINA3, the only downregulated gene examined, was not associated with survival, but correlated with steroid receptor status. An indirect validation of our genes was provided by calculating their association with survival in 3 publicly available microarray datasets. CKMT1B expression was an independent prognostic marker in all 3 datasets, whereas other genes confirmed their association with disease-free survival in at least 1 dataset. This work provides a novel set of genes that could be used as independent prognostic markers and potential drug targets for breast cancer.
通过微阵列分析研究了两组具有不同临床结局的存档乳腺癌组织中的基因表达谱。在比较30例复发患者和30例术后72个月内未复发患者时,鉴定出77个差异表达基因。这些基因具有特定的本体分布,其中一些在先前的研究中已与乳腺癌相关联:AIB1、两个角蛋白基因KRT5和KRT15、RAF1、WIF1和MSH6。从77个差异表达基因中选择了7个,并在127例乳腺癌中通过qRT-PCR进行分析。6个上调基因(CKMT1B、DDX21、PRKDC、PTPN1、SLPI、YWHAE)的表达水平与无病生存期和总生存期均显示出显著相关性。以显著因素(即雌激素受体和淋巴结状态)作为协变量的多变量分析证实了与生存期的相关性。这些基因的表达水平与其他临床参数之间无相关性。相比之下,唯一检测到的下调基因SERPINA3与生存期无关,但与类固醇受体状态相关。通过计算它们与3个公开可用微阵列数据集中生存期的关联,对我们的基因进行了间接验证。CKMT1B表达在所有3个数据集中都是独立的预后标志物,而其他基因在至少1个数据集中证实了它们与无病生存期的关联。这项工作提供了一组新的基因,可作为乳腺癌的独立预后标志物和潜在的药物靶点。